P-220: A Two Purpose Use of Orlistat in Obese Women with Polycystic Ovary Syndrome: Weight Loss and Androgen Reduction
Authors
Abstract:
Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in young women. PCOS affects 6% and 8% of women in reproductive age. Hyperandrogenism is the hallmark of PCOS. Clinically, it is possible to observe hirsutism, acne, androgenic alopecia, and signs of virilization. Laboratory examination reveals increased androgen levels. Excessive androgen has an important role in the pathophysiology of PCOS. The aim of this study was to appoint evidence based and clinically applicable advice effect of Orlistat on weight loss and serum anderogen level reduction in women with PCOS. Materials and Methods: The present study was performed in the clinic of Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical sciences, Tehran, Iran. 32 PCOS patients were enrolled randomly. The Sera of androgens (Testosterone, 17(OH) P, DHEAS, SHBG were measured before and after treatment of 12 weeks with orlistat. For all patients performed Rotterdam Criteria and transvaginal sonography for evaluation of ovarian patterns. In this study, p<0.05 was considered to indicate statistical significance. Results: The study included 32 patients. The mean age was 27.75 ± 6.22 and the mean body mass index was 32.69 ± 0.94 kg/m2. Comparing with baseline, treatment with orlistat resulted in a significant reduction in weight, BMI, and waist circumference (p=0.001). We found a remarkable reduction in total Testosterone levels (p<0.001). Treatment improved the SHBG plasma levels, but the difference was not significant. There was no reduction in other androgen levels. As an incidental findings we encountered with a 30 mm decreasing size of uterine leiomyoma. Conclusion: This study showed a significant reduction on weight and total Testosterone levels, as the most important anderogens in PCOS patients. Therefore, controlling of weight and treatment by a short course of Orlistat can be useful in management of PCOS cases.
similar resources
P-182: The Comparison of Clinical and Laboratory Characteristics in Obese and Normal Weight Women with Polycystic Ovary Syndrome
Background: The main characteristic of polycystic ovary syndrome (PCOS) is oligomenorrhea with clinical and biochemical signs of hyperandrogenism(HA) and the phenotypic spectrum of PCOS is very broad. There are very limited studies about the features of patients with PCOS in Iran. The purpose of this study is to compare the clinical and laboratory characteristics of PCOS between the overweight ...
full textMetformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.
CONTEXT Metformin treatment of women with polycystic ovary syndrome (PCOS) is widespread, as determined by studies with diverse patient populations. No comparative examination of weight changes or metabolite responses to different doses has been reported. OBJECTIVE The aim of this study was to determine whether different doses of metformin (1500 or 2550 mg/d) would have different effects on b...
full textInsulin resistance and adverse metabolic profile in overweight/obese and normal weight of young women with polycystic ovary syndrome
Background: Polycystic ovary syndrome (PCOs) is an endocrine-metabolic disorder. This study intends to determine the comparison of insulin resistance (IR) and metabolic disturbance in overweight/obese and normal-weight of young women with polycystic ovary syndrome. Methods: Using a comparative cross-sectional study design in 2015, 27 normal weight (18<bmi Results: 112 women with PCOS participa...
full textP-38: Comparison of Oxidative Stress and Antioxidative Status in non Obese Women with and without Polycystic Ovary Syndrome
full text
P-205: Effects of Aerobic Exercise on Plasma Lipoproteins in Overweight and Obese Women with Polycystic Ovary Syndrome
Background: Polycystic ovary syndrome (PCOS) is one of the most frequent endocrine disorders. Obesity and anovulation in the women affected by this syndrome leads to a type of obesity that is followed by cardiovascular disease, hypertention and cholesterol and lipoprotein improper profiles. Changing the life style, e.g. increasing physical activities is the first approach in controlling PCOS Ma...
full textvisfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome
conclusions while the expression of visfatin and resistin may be upregulated in women with pcos, it is not translated at serum level. results serum levels of resistin were higher among both obese and normal-weight women with pcos in comparison with the controls (2.36 and 1.58 ng/ml in normal-weight women with pcos and controls, respectively; and 2.10 and 1.91 ng/ml in obese women with pcos and ...
full textMy Resources
Journal title
volume 8 issue 2.5
pages 231- 231
publication date 2014-07-01
By following a journal you will be notified via email when a new issue of this journal is published.
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023